title: 6MP for fathers with IBD at the time of conception: the value of a large clinical experience over unrelated controls.
authors.forename: B I
authors.initials: BI
authors.lastname: Korelitz
authors.forename: R O
authors.initials: RO
authors.lastname: Rajapakse
authors.forename: J
authors.initials: J
authors.lastname: Zlatanic
authors.forename: P J
authors.initials: PJ
authors.lastname: Baiocco
authors.forename: G W
authors.initials: GW
authors.lastname: Gleim
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005306:Fertilization / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D007231:Infant, Newborn; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use*; D018812:Paternal Exposure / Q000009:adverse effects; D011247:Pregnancy; D011256:Pregnancy Outcome; D012307:Risk Factors
chemical_list: D007166:Immunosuppressive Agents; D015122:Mercaptopurine